摘要
目的分析贵州省2004年Ⅰ型循环的疫苗衍生脊髓灰质炎(脊灰)病毒(cVDPVs)的基因特征,阐述cVDPVs的出现为全球消灭脊灰带来的挑战。方法2004年中国疾病预防控制中心(CDC)病毒病预防控制所国家脊灰实验室对各个省送检的每1个脊灰病毒分离株进行聚合酶链反应-限制性酶切片段长度多态性分析(PCR-RFLP)和酶联免疫吸附试验(ELISA)两种方法的型内鉴定。毒株型内鉴别显示异常时,则对该株病毒进行VP1编码区全基因的序列测定和分析。结果2004年从贵州省CDC送检的脊灰病毒株(或粪便标本的复核)中,共发现9株Ⅰ型疫苗衍生脊灰病毒(VDPVs)。这9株VDPVs从2例急性弛缓性麻痹(AFP)病例和4名接触者的粪便标本中分离到。其中8株分离于贞丰县挽兰乡的2例AFP病例和3名接触者,另外1株分离于贞丰县白层镇的1名AFP病例接触者。结论对9株cVDPVs的VP1编码区的序列测定和分析证实,它们有相似的核苷酸序列,共享5个核苷酸突变位点,说明VDPVs已发生了循环。cVDPVs很可能来源于2003年秋季的1次口服脊灰减毒活疫苗病毒的传播。对其中5株VDPVs的3D区和1株VDPV(8229-2)的全序列测定和分析,未发现脊灰病毒血清型之间的重组,也未发现与非脊灰肠道病毒的重组。
Objective To elucidate the challenge of cVDPVs bringing to the global polioviruses eradication,the genetic characters were analyzed for Guizhou type Ⅰ cVDPVs. Method In 2004, National Laboratory for Poliomyelitis used RT-PCR-RFLP and ELISA as routine intratypic differentiation methods to identify all the poliovirus isolates refered by 31 provincial laboratory for poliomyelitis,if the results were aberrant compared with Sabin strains, VP1 sequencing was need for further identification. Results From January to December in 2004, total 9 type Ⅰ vaccine-derived polioviruses（VDPVs） were isolated from the virus isolates （including original stool samples for confirmation）referred by Guizhou Provincial Laboratory for Poliomyelitis. These 9 VDPVs were isolated from two AFP cases and four contactors in Zhenfeng County, Qianxinan Prefecture, Guizhou Province, China, among these isolates,8 were isolated from two AFP cases and three contactors in Wanlan Village, and another 1 isolated from a contactor of another AFP case in Baiceng Village. Conclusion All 9 isolates were similar in viral nucleotide sequences through VP1 sequencing,and they shared 5 mutant points,so it isstrongly suggested that the circulating is due to only one linage and maybe derived from a single OPV infection in autumn in 2003. 3D ,sequence analysis for 5 strains and complete genome sequence analysis for 1 strain （8229-1.2）showed no recombinations occurred among different serotype poliovirus es or among poliovirus and several NPEVs.
出处
《中国计划免疫》
2005年第4期252-259,共8页
Chinese Journal of Vaccines and Immunization
基金
世界卫生组织(18/181/896)
卫生部疾病控制专项(2004年)
